Form 483 Observations Are Not GMP Guidance, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Industry should not use observations from FDA-483 reports as good manufacturing practices guidance, CDER Office of Compliance Director David Horowitz said.